# Dishman Pharma (NSE: DPC02) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/DPC02 · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹2,676 Cr, it ranks 1022nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.

Its return on equity was 11.8% in FY16.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹2,676 Cr |
| ROE | 11.8% (FY16) |
| ROCE | 8.4% (FY16) |
| Debt to equity | 0.58 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY16 | ₹1,596 Cr | ₹171 Cr |
| FY15 | ₹1,575 Cr | ₹120 Cr |
| FY14 | ₹1,385 Cr | ₹109 Cr |
| FY13 | ₹1,272 Cr | ₹100 Cr |
| FY12 | ₹1,124 Cr | ₹57 Cr |
| FY11 | ₹1,031 Cr | ₹80 Cr |

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Advanced Enzyme Technologies](https://app.pivotnow.in/stock/ADVENZYMES) | ₹265.45 | ₹2,972 Cr | 17.6 | — |
| [Shukra Pharma](https://app.pivotnow.in/stock/SHUKRAPHAR) | ₹63.62 | ₹2,797 Cr | 127.2 | — |
| [Hikal](https://app.pivotnow.in/stock/HIKAL) | ₹210.01 | ₹2,589 Cr | — | — |
| [Dr Agarwals Eye Hospital](https://app.pivotnow.in/stock/DRAGARWQ) | ₹5,025.00 | ₹2,428 Cr | — | — |
| [Venus Remedies](https://app.pivotnow.in/stock/VENUSREM) | ₹1,796.10 | ₹2,401 Cr | 23.3 | — |
| [Alembic](https://app.pivotnow.in/stock/ALEMBICLTD) | ₹92.33 | ₹2,371 Cr | 7.5 | — |

## Questions and answers

### What is the market cap of Dishman Pharma?

Dishman Pharma's market capitalisation is ₹2,676 Cr (₹2,676 Cr) at the 22 Oct 2026 close, ranking 1022nd among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Dishman Pharma?

Return on equity was 11.8% in FY16 and return on capital employed was 8.4% in FY16 (consolidated figures).

### Is Dishman Pharma a debt-free company?

No. Dishman Pharma's debt-to-equity ratio was 0.58 in FY16, with total debt of ₹419 Cr.

### Who are Dishman Pharma's competitors?

The listed Pharma & Healthcare companies closest to Dishman Pharma by market cap are Advanced Enzyme Technologies, Shukra Pharma, Hikal, Dr Agarwals Eye Hospital, Venus Remedies and Alembic.

### Is Dishman Pharma a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Dishman Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on DPC02 against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.